Top Markets
#1 Pleasing Gold Pleasing Gold +738.04%
#2 Islamic Coin Islamic Coin +154.23%
#3 PulseChain PulseChain +56.20%
#4 BOOK OF MEME BOOK OF MEME +40.59%
#5 DogBull DogBull +37.66%
#6 Collect on Fanable Collect on Fanable +26.22%
#7 Nockchain Nockchain +20.02%
#8 Neiro Neiro +18.83%
#9 rsERG rsERG +17.72%
#10 PondCoin PondCoin +17.19%
Coin of the day
Pleasing Gold Pleasing Gold
Settings
Language
ENGLISH
Currency
USD
Theme
Oncoinvent ASA Oncoinvent ASA

Oncoinvent ASA

ONCIN
Rank in Stocks #26813
Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to... Oncoinvent ASA, a clinical-stage firm based in Oslo, Norway, is dedicated to developing innovative radiopharmaceutical treatments for various cancers. Its primary therapeutic agent is Radspherin, an alpha-emitting radiotherapeutic, which is currently undergoing investigation in two Phase 1/2a and one randomized Phase 2 clinical trials. This promising candidate is designed to target and treat malignancies that have metastasized to body cavities, specifically including the peritoneum.
Share Price
$8.39
Market Cap
$37.55M
Change (1 day)
-7.83%
Change (1 year)
-26.06%
Country
NO
Trade Oncoinvent ASA (ONCIN)

Category

Healthcare
P/S ratio for Oncoinvent ASA (ONCIN)
P/S ratio as of 2026 TTM: 0
According to Oncoinvent ASA latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0. At the end of 2026 the company had a P/S ratio of 0.
P/S ratio history for Oncoinvent ASA from 2026 to 2026
P/S ratio at the end of each year
Year P/S Ratio Change
Not enough data for the provided dates.
P/S ratio for similar companies or competitors
Company P/S Ratio P/S Ratio Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
10.17 -
US
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
11.28 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
10.13 -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
2.95 -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH